Page 29 - Wondergem

87. Da Villa D, Crump M, Keating A, Panzarella T, Feng B, Kuruvilla J. Outcome of patients with transformed 1 indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. Ann Oncol. 2013;24(6):1603-1609.
88. Williams CD, Harrison CN, Lister TA et al. European Bone Marrow Transplant Lymphoma Working Party. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-hodgkin’s lymphoma: a case matched study from the European Bone Marow Transplant Registry. J Clin Oncol. 2001;19(3):727-735.
89. Clavert A, le Gouill S, Brissot E et al. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2010;51(8):1502-1508
90. Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. B J Haematol 2005;131:223-230
91. Hamadani M, Farukh TA, Elder P et al. Feasability of allogeneic haematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B cell lymphoma. Leuk Lymphoma 2008;49(10):1893-1898
92. Khouri IF, Keating M, Körbling M et al. Transplant-lite: induction of graft vs malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824
93. Mortensen BK, Petersen SL, Kornblit B et al. Single-institution lon-term outcomes for patients receiving nonmyeloablative conditioning hematopoetic cell transplantation for chronic lymphocytic leukemia and follicular lymphoma. Eur J Haematol 2012;89:151-159
94. Novitzky N, Thomas V. Allogeneic stem cell transplantation with T-cell depleted grafts for lymphoproliferative malignancies. Biol Blood Marrow Transplant 2007;13:107-115
95. Ramadan KM, Connors JM, Al-Tourah AJ et al. Allogeneic stem cell transplantation for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 2008;42:601-608
96. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation in relapsed, refractory and transformed indolent non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:211-217
97. Thomson KJ, Morris EC, Bloor A, Cook G, Milligan D, Parker A et al. Favourable long term survival after reduced-intensity alloSCT for multiple-relapse aggressive NHL. J Clin Oncol 2008;27:426-432
98. Morley NJ, Evans LS, Goepel J and Hancock BW. Transformed follicular lymphoma: the 25-year experience of a UK provincial lymphoma treatment centre. Oncol Rep 2008;20:953-956
99. Reddy N, Oluwole O, Greer JP et al. Superior lon-term outcome of patients with early transformation of non- Hodgkin lymphoma undergoing stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2012;12(6):406- 411
100. RoyR,EvensAM,PattonD,etal.BortezomibmaybesafelycombinedwithY-90-ibritumomabtiuxetanin patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. Leuk Lymphoma 2013;54(3):497-502
101. AbdulwahabJ,Al-TourahAJ,Savage,KJ,GillKK,KlasaRJ,SehnL,ShenklerTN,GascoyneRD,ConnorsJM. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. Blood ASH annual meeting abstracts Nov 2007:110: abstract 790
102. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic stem cell transplantation. Blood 2009;114:7-19
103. PalluaS,GiesingerJ,OberguggenbergerAetal.ImpactofGvHDonqualityoflifeinlong-termsurvivorsof haematopoietic transplantation. Bone Marrow Transplant 2010:1-6
104. Schimmer AD, Jamal S, Messner H et al. Allogeneic or autologous bone marrow transplantation for non- Hodgkin’s lymphoma: results of a provincial strategy. Ontario BMT network, Canada. Bone marrow transplant 2000;26(8): 859-864
105. MorrisE,ThomsonK,CraddockC,MahendraP,MilliganD,CookGetal.Outcomesafteralemtuzumab- containing reduced-intensity allogeneic transplantation for relapsed and refractory non-hodgkin lymphoma. Blood 2004;104:3865-3871
106. HamadaniM,BensonDM,HofmeisterCC,ElderP,BlumW,PorcuPetal.Allogeneicstemcelltransplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant 2009;15:547-553
Introduction and scope of this thesis
27